Global Orphan Drugs

Orphan Drugs Comprehensive Study by Drug Type (Biologics, Non-Biologics), Sale (Generics, Prescribed), Drugs (Revlimid, Rituxan, Opdivo, Others), Disease Type (Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic disorders, Endocrinology, Infectious diseases, Others), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail pharmacies, Others) Players and Region - Global Market Outlook to 2027

Orphan Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Orphan Drugs Market?

Germany had the highest approval rate of orphan drugs at 98% however, most of these recommendations (73%) were awarded a ‘non-quantifiable benefit’ rating, the automatic rating for an orphan drug, which shows the regulator did not see any benefit compared to comparator products Orphan drugs are the drugs used to treat, prevent, or diagnose an orphan disease. An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan diseases are often serious or life-threatening. In 1983, the United States government passed a law, called the Orphan Drug Act, to give drug companies certain financial benefits for developing orphan drugs that are safe and effective.

Highlights from Orphan Drugs Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledNovartis International AG (Switzerland), Bristol Myers Squibb (United States), Celgene (United States), Roche Holding AG (Switzerland), Pfizer Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk (Denmark), AstraZeneca plc (United Kingdom), Eisai Co., Ltd. (Japan), Daiichi Sankyo Company (Japan), Bayer (Germany), GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Johnson & Johnson (United States) and Biogen Inc. (Switzerland)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Orphan Drugs market throughout the forecasted period.

Novartis International AG (Switzerland), Bristol Myers Squibb (United States), Celgene (United States), Roche Holding AG (Switzerland), Pfizer Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk (Denmark), AstraZeneca plc (United Kingdom), Eisai Co., Ltd. (Japan), Daiichi Sankyo Company (Japan), Bayer (Germany), GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Johnson & Johnson (United States) and Biogen Inc. (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Shire Plc (United States) and Amgen Inc. (United States).

Orphan Drugs Market Segmentation:
ScopeSub-Segments
Drug TypeBiologics,Non-Biologics
SaleGenerics,Prescribed
DrugsRevlimid,Rituxan,Opdivo,Others
Disease TypeOncology,Gastrointestinal,Pulmonary,Neurology,Hematology,Cardio-vascular,Metabolic disorders,Endocrinology,Infectious diseases,Others
Distribution ChannelHospital Pharmacies,Specialty Pharmacies,Retail pharmacies,Others


On the basis of geography, the market of Orphan Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Medical Science and Increased Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Rare Diseases and Increased Government Funding

Challenges:
Lack of Healthcare Infrastructure in Under Developed Countries

Restraints:
High Treatment Cost per Patient

Opportunities:
Growth in the Healthcare Industry and Increasing Number of Online Pharmacies

Key Target Audience
Orphan Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

In November 2019, The United States Food and Drug Administration (FDA) approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions. The approval marks the first approved treatment in the United States for this condition. The approval also marks the first for Acceleron, which sent shares up nearly 7% in afternoon trading. Reblozyl, an erythroid maturation agent, was approved under Fast Track Designation and the drug received Orphan Drug designation.


Report Objectives / Segmentation Covered

By Drug Type
  • Biologics
  • Non-Biologics

By Sale
  • Generics
  • Prescribed

By Drugs
  • Revlimid
  • Rituxan
  • Opdivo
  • Others

By Disease Type
  • Oncology
  • Gastrointestinal
  • Pulmonary
  • Neurology
  • Hematology
  • Cardio-vascular
  • Metabolic disorders
  • Endocrinology
  • Infectious diseases
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Rare Diseases
      • 3.2.2. Increased Government Funding
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Under Developed Countries
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Medical Science
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Orphan Drugs, by Drug Type, Sale, Drugs, Disease Type, Distribution Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Orphan Drugs (Value)
      • 5.2.1. Global Orphan Drugs by: Drug Type (Value)
        • 5.2.1.1. Biologics
        • 5.2.1.2. Non-Biologics
      • 5.2.2. Global Orphan Drugs by: Sale (Value)
        • 5.2.2.1. Generics
        • 5.2.2.2. Prescribed
      • 5.2.3. Global Orphan Drugs by: Drugs (Value)
        • 5.2.3.1. Revlimid
        • 5.2.3.2. Rituxan
        • 5.2.3.3. Opdivo
        • 5.2.3.4. Others
      • 5.2.4. Global Orphan Drugs by: Disease Type (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Gastrointestinal
        • 5.2.4.3. Pulmonary
        • 5.2.4.4. Neurology
        • 5.2.4.5. Hematology
        • 5.2.4.6. Cardio-vascular
        • 5.2.4.7. Metabolic disorders
        • 5.2.4.8. Endocrinology
        • 5.2.4.9. Infectious diseases
        • 5.2.4.10. Others
      • 5.2.5. Global Orphan Drugs by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Specialty Pharmacies
        • 5.2.5.3. Retail pharmacies
        • 5.2.5.4. Others
      • 5.2.6. Global Orphan Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Orphan Drugs (Volume)
      • 5.3.1. Global Orphan Drugs by: Drug Type (Volume)
        • 5.3.1.1. Biologics
        • 5.3.1.2. Non-Biologics
      • 5.3.2. Global Orphan Drugs by: Sale (Volume)
        • 5.3.2.1. Generics
        • 5.3.2.2. Prescribed
      • 5.3.3. Global Orphan Drugs by: Drugs (Volume)
        • 5.3.3.1. Revlimid
        • 5.3.3.2. Rituxan
        • 5.3.3.3. Opdivo
        • 5.3.3.4. Others
      • 5.3.4. Global Orphan Drugs by: Disease Type (Volume)
        • 5.3.4.1. Oncology
        • 5.3.4.2. Gastrointestinal
        • 5.3.4.3. Pulmonary
        • 5.3.4.4. Neurology
        • 5.3.4.5. Hematology
        • 5.3.4.6. Cardio-vascular
        • 5.3.4.7. Metabolic disorders
        • 5.3.4.8. Endocrinology
        • 5.3.4.9. Infectious diseases
        • 5.3.4.10. Others
      • 5.3.5. Global Orphan Drugs by: Distribution Channel (Volume)
        • 5.3.5.1. Hospital Pharmacies
        • 5.3.5.2. Specialty Pharmacies
        • 5.3.5.3. Retail pharmacies
        • 5.3.5.4. Others
      • 5.3.6. Global Orphan Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Orphan Drugs (Price)
  • 6. Orphan Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alexion Pharmaceuticals Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novo Nordisk (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eisai Co., Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Daiichi Sankyo Company (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bayer (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. GlaxoSmithKline (United Kingdom)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Merck & Co., Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Johnson & Johnson (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Biogen Inc. (Switzerland)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Orphan Drugs Sale, by Drug Type, Sale, Drugs, Disease Type, Distribution Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Orphan Drugs (Value)
      • 7.2.1. Global Orphan Drugs by: Drug Type (Value)
        • 7.2.1.1. Biologics
        • 7.2.1.2. Non-Biologics
      • 7.2.2. Global Orphan Drugs by: Sale (Value)
        • 7.2.2.1. Generics
        • 7.2.2.2. Prescribed
      • 7.2.3. Global Orphan Drugs by: Drugs (Value)
        • 7.2.3.1. Revlimid
        • 7.2.3.2. Rituxan
        • 7.2.3.3. Opdivo
        • 7.2.3.4. Others
      • 7.2.4. Global Orphan Drugs by: Disease Type (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Gastrointestinal
        • 7.2.4.3. Pulmonary
        • 7.2.4.4. Neurology
        • 7.2.4.5. Hematology
        • 7.2.4.6. Cardio-vascular
        • 7.2.4.7. Metabolic disorders
        • 7.2.4.8. Endocrinology
        • 7.2.4.9. Infectious diseases
        • 7.2.4.10. Others
      • 7.2.5. Global Orphan Drugs by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Specialty Pharmacies
        • 7.2.5.3. Retail pharmacies
        • 7.2.5.4. Others
      • 7.2.6. Global Orphan Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Orphan Drugs (Volume)
      • 7.3.1. Global Orphan Drugs by: Drug Type (Volume)
        • 7.3.1.1. Biologics
        • 7.3.1.2. Non-Biologics
      • 7.3.2. Global Orphan Drugs by: Sale (Volume)
        • 7.3.2.1. Generics
        • 7.3.2.2. Prescribed
      • 7.3.3. Global Orphan Drugs by: Drugs (Volume)
        • 7.3.3.1. Revlimid
        • 7.3.3.2. Rituxan
        • 7.3.3.3. Opdivo
        • 7.3.3.4. Others
      • 7.3.4. Global Orphan Drugs by: Disease Type (Volume)
        • 7.3.4.1. Oncology
        • 7.3.4.2. Gastrointestinal
        • 7.3.4.3. Pulmonary
        • 7.3.4.4. Neurology
        • 7.3.4.5. Hematology
        • 7.3.4.6. Cardio-vascular
        • 7.3.4.7. Metabolic disorders
        • 7.3.4.8. Endocrinology
        • 7.3.4.9. Infectious diseases
        • 7.3.4.10. Others
      • 7.3.5. Global Orphan Drugs by: Distribution Channel (Volume)
        • 7.3.5.1. Hospital Pharmacies
        • 7.3.5.2. Specialty Pharmacies
        • 7.3.5.3. Retail pharmacies
        • 7.3.5.4. Others
      • 7.3.6. Global Orphan Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Orphan Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Orphan Drugs: by Drug Type(USD Million)
  • Table 2. Orphan Drugs Biologics , by Region USD Million (2016-2021)
  • Table 3. Orphan Drugs Non-Biologics , by Region USD Million (2016-2021)
  • Table 4. Orphan Drugs: by Sale(USD Million)
  • Table 5. Orphan Drugs Generics , by Region USD Million (2016-2021)
  • Table 6. Orphan Drugs Prescribed , by Region USD Million (2016-2021)
  • Table 7. Orphan Drugs: by Drugs(USD Million)
  • Table 8. Orphan Drugs Revlimid , by Region USD Million (2016-2021)
  • Table 9. Orphan Drugs Rituxan , by Region USD Million (2016-2021)
  • Table 10. Orphan Drugs Opdivo , by Region USD Million (2016-2021)
  • Table 11. Orphan Drugs Others , by Region USD Million (2016-2021)
  • Table 12. Orphan Drugs: by Disease Type(USD Million)
  • Table 13. Orphan Drugs Oncology , by Region USD Million (2016-2021)
  • Table 14. Orphan Drugs Gastrointestinal , by Region USD Million (2016-2021)
  • Table 15. Orphan Drugs Pulmonary , by Region USD Million (2016-2021)
  • Table 16. Orphan Drugs Neurology , by Region USD Million (2016-2021)
  • Table 17. Orphan Drugs Hematology , by Region USD Million (2016-2021)
  • Table 18. Orphan Drugs Cardio-vascular , by Region USD Million (2016-2021)
  • Table 19. Orphan Drugs Metabolic disorders , by Region USD Million (2016-2021)
  • Table 20. Orphan Drugs Endocrinology , by Region USD Million (2016-2021)
  • Table 21. Orphan Drugs Infectious diseases , by Region USD Million (2016-2021)
  • Table 22. Orphan Drugs Others , by Region USD Million (2016-2021)
  • Table 23. Orphan Drugs: by Distribution Channel(USD Million)
  • Table 24. Orphan Drugs Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 25. Orphan Drugs Specialty Pharmacies , by Region USD Million (2016-2021)
  • Table 26. Orphan Drugs Retail pharmacies , by Region USD Million (2016-2021)
  • Table 27. Orphan Drugs Others , by Region USD Million (2016-2021)
  • Table 28. South America Orphan Drugs, by Country USD Million (2016-2021)
  • Table 29. South America Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 30. South America Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 31. South America Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 32. South America Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 33. South America Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 34. Brazil Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 35. Brazil Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 36. Brazil Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 37. Brazil Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 38. Brazil Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 39. Argentina Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 40. Argentina Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 41. Argentina Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 42. Argentina Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 43. Argentina Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 44. Rest of South America Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 45. Rest of South America Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 46. Rest of South America Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 47. Rest of South America Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 48. Rest of South America Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 49. Asia Pacific Orphan Drugs, by Country USD Million (2016-2021)
  • Table 50. Asia Pacific Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 51. Asia Pacific Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 52. Asia Pacific Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 53. Asia Pacific Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 54. Asia Pacific Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 55. China Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 56. China Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 57. China Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 58. China Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 59. China Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 60. Japan Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 61. Japan Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 62. Japan Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 63. Japan Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 64. Japan Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 65. India Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 66. India Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 67. India Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 68. India Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 69. India Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 70. South Korea Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 71. South Korea Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 72. South Korea Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 73. South Korea Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 74. South Korea Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 75. Taiwan Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 76. Taiwan Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 77. Taiwan Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 78. Taiwan Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 79. Taiwan Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 80. Australia Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 81. Australia Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 82. Australia Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 83. Australia Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 84. Australia Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 85. Rest of Asia-Pacific Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 86. Rest of Asia-Pacific Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 87. Rest of Asia-Pacific Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 88. Rest of Asia-Pacific Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 89. Rest of Asia-Pacific Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 90. Europe Orphan Drugs, by Country USD Million (2016-2021)
  • Table 91. Europe Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 92. Europe Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 93. Europe Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 94. Europe Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 95. Europe Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 96. Germany Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 97. Germany Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 98. Germany Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 99. Germany Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 100. Germany Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 101. France Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 102. France Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 103. France Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 104. France Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 105. France Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 106. Italy Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 107. Italy Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 108. Italy Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 109. Italy Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 110. Italy Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 111. United Kingdom Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 112. United Kingdom Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 113. United Kingdom Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 114. United Kingdom Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 115. United Kingdom Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 116. Netherlands Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 117. Netherlands Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 118. Netherlands Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 119. Netherlands Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 120. Netherlands Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 121. Rest of Europe Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 122. Rest of Europe Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 123. Rest of Europe Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 124. Rest of Europe Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 125. Rest of Europe Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 126. MEA Orphan Drugs, by Country USD Million (2016-2021)
  • Table 127. MEA Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 128. MEA Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 129. MEA Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 130. MEA Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 131. MEA Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 132. Middle East Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 133. Middle East Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 134. Middle East Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 135. Middle East Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 136. Middle East Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 137. Africa Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 138. Africa Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 139. Africa Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 140. Africa Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 141. Africa Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 142. North America Orphan Drugs, by Country USD Million (2016-2021)
  • Table 143. North America Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 144. North America Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 145. North America Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 146. North America Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 147. North America Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 148. United States Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 149. United States Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 150. United States Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 151. United States Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 152. United States Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 153. Canada Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 154. Canada Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 155. Canada Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 156. Canada Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 157. Canada Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 158. Mexico Orphan Drugs, by Drug Type USD Million (2016-2021)
  • Table 159. Mexico Orphan Drugs, by Sale USD Million (2016-2021)
  • Table 160. Mexico Orphan Drugs, by Drugs USD Million (2016-2021)
  • Table 161. Mexico Orphan Drugs, by Disease Type USD Million (2016-2021)
  • Table 162. Mexico Orphan Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 163. Orphan Drugs Sales: by Drug Type(K Units)
  • Table 164. Orphan Drugs Sales Biologics , by Region K Units (2016-2021)
  • Table 165. Orphan Drugs Sales Non-Biologics , by Region K Units (2016-2021)
  • Table 166. Orphan Drugs Sales: by Sale(K Units)
  • Table 167. Orphan Drugs Sales Generics , by Region K Units (2016-2021)
  • Table 168. Orphan Drugs Sales Prescribed , by Region K Units (2016-2021)
  • Table 169. Orphan Drugs Sales: by Drugs(K Units)
  • Table 170. Orphan Drugs Sales Revlimid , by Region K Units (2016-2021)
  • Table 171. Orphan Drugs Sales Rituxan , by Region K Units (2016-2021)
  • Table 172. Orphan Drugs Sales Opdivo , by Region K Units (2016-2021)
  • Table 173. Orphan Drugs Sales Others , by Region K Units (2016-2021)
  • Table 174. Orphan Drugs Sales: by Disease Type(K Units)
  • Table 175. Orphan Drugs Sales Oncology , by Region K Units (2016-2021)
  • Table 176. Orphan Drugs Sales Gastrointestinal , by Region K Units (2016-2021)
  • Table 177. Orphan Drugs Sales Pulmonary , by Region K Units (2016-2021)
  • Table 178. Orphan Drugs Sales Neurology , by Region K Units (2016-2021)
  • Table 179. Orphan Drugs Sales Hematology , by Region K Units (2016-2021)
  • Table 180. Orphan Drugs Sales Cardio-vascular , by Region K Units (2016-2021)
  • Table 181. Orphan Drugs Sales Metabolic disorders , by Region K Units (2016-2021)
  • Table 182. Orphan Drugs Sales Endocrinology , by Region K Units (2016-2021)
  • Table 183. Orphan Drugs Sales Infectious diseases , by Region K Units (2016-2021)
  • Table 184. Orphan Drugs Sales Others , by Region K Units (2016-2021)
  • Table 185. Orphan Drugs Sales: by Distribution Channel(K Units)
  • Table 186. Orphan Drugs Sales Hospital Pharmacies , by Region K Units (2016-2021)
  • Table 187. Orphan Drugs Sales Specialty Pharmacies , by Region K Units (2016-2021)
  • Table 188. Orphan Drugs Sales Retail pharmacies , by Region K Units (2016-2021)
  • Table 189. Orphan Drugs Sales Others , by Region K Units (2016-2021)
  • Table 190. South America Orphan Drugs Sales, by Country K Units (2016-2021)
  • Table 191. South America Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 192. South America Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 193. South America Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 194. South America Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 195. South America Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 196. Brazil Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 197. Brazil Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 198. Brazil Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 199. Brazil Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 200. Brazil Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 201. Argentina Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 202. Argentina Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 203. Argentina Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 204. Argentina Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 205. Argentina Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 206. Rest of South America Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 207. Rest of South America Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 208. Rest of South America Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 209. Rest of South America Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 210. Rest of South America Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 211. Asia Pacific Orphan Drugs Sales, by Country K Units (2016-2021)
  • Table 212. Asia Pacific Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 213. Asia Pacific Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 214. Asia Pacific Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 215. Asia Pacific Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 216. Asia Pacific Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 217. China Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 218. China Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 219. China Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 220. China Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 221. China Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 222. Japan Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 223. Japan Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 224. Japan Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 225. Japan Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 226. Japan Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 227. India Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 228. India Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 229. India Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 230. India Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 231. India Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 232. South Korea Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 233. South Korea Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 234. South Korea Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 235. South Korea Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 236. South Korea Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 237. Taiwan Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 238. Taiwan Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 239. Taiwan Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 240. Taiwan Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 241. Taiwan Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 242. Australia Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 243. Australia Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 244. Australia Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 245. Australia Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 246. Australia Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 247. Rest of Asia-Pacific Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 248. Rest of Asia-Pacific Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 249. Rest of Asia-Pacific Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 250. Rest of Asia-Pacific Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 251. Rest of Asia-Pacific Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 252. Europe Orphan Drugs Sales, by Country K Units (2016-2021)
  • Table 253. Europe Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 254. Europe Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 255. Europe Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 256. Europe Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 257. Europe Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 258. Germany Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 259. Germany Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 260. Germany Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 261. Germany Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 262. Germany Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 263. France Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 264. France Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 265. France Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 266. France Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 267. France Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 268. Italy Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 269. Italy Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 270. Italy Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 271. Italy Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 272. Italy Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 273. United Kingdom Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 274. United Kingdom Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 275. United Kingdom Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 276. United Kingdom Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 277. United Kingdom Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 278. Netherlands Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 279. Netherlands Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 280. Netherlands Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 281. Netherlands Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 282. Netherlands Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 283. Rest of Europe Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 284. Rest of Europe Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 285. Rest of Europe Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 286. Rest of Europe Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 287. Rest of Europe Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 288. MEA Orphan Drugs Sales, by Country K Units (2016-2021)
  • Table 289. MEA Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 290. MEA Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 291. MEA Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 292. MEA Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 293. MEA Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 294. Middle East Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 295. Middle East Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 296. Middle East Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 297. Middle East Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 298. Middle East Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 299. Africa Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 300. Africa Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 301. Africa Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 302. Africa Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 303. Africa Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 304. North America Orphan Drugs Sales, by Country K Units (2016-2021)
  • Table 305. North America Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 306. North America Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 307. North America Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 308. North America Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 309. North America Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 310. United States Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 311. United States Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 312. United States Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 313. United States Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 314. United States Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 315. Canada Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 316. Canada Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 317. Canada Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 318. Canada Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 319. Canada Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 320. Mexico Orphan Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 321. Mexico Orphan Drugs Sales, by Sale K Units (2016-2021)
  • Table 322. Mexico Orphan Drugs Sales, by Drugs K Units (2016-2021)
  • Table 323. Mexico Orphan Drugs Sales, by Disease Type K Units (2016-2021)
  • Table 324. Mexico Orphan Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Company Basic Information, Sales Area and Its Competitors
  • Table 339. Company Basic Information, Sales Area and Its Competitors
  • Table 340. Company Basic Information, Sales Area and Its Competitors
  • Table 341. Company Basic Information, Sales Area and Its Competitors
  • Table 342. Orphan Drugs: by Drug Type(USD Million)
  • Table 343. Orphan Drugs Biologics , by Region USD Million (2022-2027)
  • Table 344. Orphan Drugs Non-Biologics , by Region USD Million (2022-2027)
  • Table 345. Orphan Drugs: by Sale(USD Million)
  • Table 346. Orphan Drugs Generics , by Region USD Million (2022-2027)
  • Table 347. Orphan Drugs Prescribed , by Region USD Million (2022-2027)
  • Table 348. Orphan Drugs: by Drugs(USD Million)
  • Table 349. Orphan Drugs Revlimid , by Region USD Million (2022-2027)
  • Table 350. Orphan Drugs Rituxan , by Region USD Million (2022-2027)
  • Table 351. Orphan Drugs Opdivo , by Region USD Million (2022-2027)
  • Table 352. Orphan Drugs Others , by Region USD Million (2022-2027)
  • Table 353. Orphan Drugs: by Disease Type(USD Million)
  • Table 354. Orphan Drugs Oncology , by Region USD Million (2022-2027)
  • Table 355. Orphan Drugs Gastrointestinal , by Region USD Million (2022-2027)
  • Table 356. Orphan Drugs Pulmonary , by Region USD Million (2022-2027)
  • Table 357. Orphan Drugs Neurology , by Region USD Million (2022-2027)
  • Table 358. Orphan Drugs Hematology , by Region USD Million (2022-2027)
  • Table 359. Orphan Drugs Cardio-vascular , by Region USD Million (2022-2027)
  • Table 360. Orphan Drugs Metabolic disorders , by Region USD Million (2022-2027)
  • Table 361. Orphan Drugs Endocrinology , by Region USD Million (2022-2027)
  • Table 362. Orphan Drugs Infectious diseases , by Region USD Million (2022-2027)
  • Table 363. Orphan Drugs Others , by Region USD Million (2022-2027)
  • Table 364. Orphan Drugs: by Distribution Channel(USD Million)
  • Table 365. Orphan Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 366. Orphan Drugs Specialty Pharmacies , by Region USD Million (2022-2027)
  • Table 367. Orphan Drugs Retail pharmacies , by Region USD Million (2022-2027)
  • Table 368. Orphan Drugs Others , by Region USD Million (2022-2027)
  • Table 369. South America Orphan Drugs, by Country USD Million (2022-2027)
  • Table 370. South America Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 371. South America Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 372. South America Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 373. South America Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 374. South America Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 375. Brazil Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 376. Brazil Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 377. Brazil Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 378. Brazil Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 379. Brazil Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 380. Argentina Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 381. Argentina Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 382. Argentina Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 383. Argentina Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 384. Argentina Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 385. Rest of South America Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 386. Rest of South America Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 387. Rest of South America Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 388. Rest of South America Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 389. Rest of South America Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 390. Asia Pacific Orphan Drugs, by Country USD Million (2022-2027)
  • Table 391. Asia Pacific Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 392. Asia Pacific Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 393. Asia Pacific Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 394. Asia Pacific Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 395. Asia Pacific Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 396. China Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 397. China Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 398. China Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 399. China Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 400. China Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 401. Japan Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 402. Japan Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 403. Japan Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 404. Japan Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 405. Japan Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 406. India Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 407. India Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 408. India Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 409. India Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 410. India Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 411. South Korea Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 412. South Korea Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 413. South Korea Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 414. South Korea Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 415. South Korea Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 416. Taiwan Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 417. Taiwan Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 418. Taiwan Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 419. Taiwan Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 420. Taiwan Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 421. Australia Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 422. Australia Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 423. Australia Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 424. Australia Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 425. Australia Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 426. Rest of Asia-Pacific Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 427. Rest of Asia-Pacific Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 428. Rest of Asia-Pacific Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 429. Rest of Asia-Pacific Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 430. Rest of Asia-Pacific Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 431. Europe Orphan Drugs, by Country USD Million (2022-2027)
  • Table 432. Europe Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 433. Europe Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 434. Europe Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 435. Europe Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 436. Europe Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 437. Germany Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 438. Germany Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 439. Germany Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 440. Germany Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 441. Germany Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 442. France Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 443. France Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 444. France Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 445. France Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 446. France Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 447. Italy Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 448. Italy Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 449. Italy Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 450. Italy Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 451. Italy Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 452. United Kingdom Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 453. United Kingdom Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 454. United Kingdom Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 455. United Kingdom Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 456. United Kingdom Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 457. Netherlands Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 458. Netherlands Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 459. Netherlands Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 460. Netherlands Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 461. Netherlands Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 462. Rest of Europe Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 463. Rest of Europe Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 464. Rest of Europe Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 465. Rest of Europe Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 466. Rest of Europe Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 467. MEA Orphan Drugs, by Country USD Million (2022-2027)
  • Table 468. MEA Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 469. MEA Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 470. MEA Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 471. MEA Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 472. MEA Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 473. Middle East Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 474. Middle East Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 475. Middle East Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 476. Middle East Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 477. Middle East Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 478. Africa Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 479. Africa Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 480. Africa Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 481. Africa Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 482. Africa Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 483. North America Orphan Drugs, by Country USD Million (2022-2027)
  • Table 484. North America Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 485. North America Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 486. North America Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 487. North America Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 488. North America Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 489. United States Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 490. United States Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 491. United States Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 492. United States Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 493. United States Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 494. Canada Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 495. Canada Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 496. Canada Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 497. Canada Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 498. Canada Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 499. Mexico Orphan Drugs, by Drug Type USD Million (2022-2027)
  • Table 500. Mexico Orphan Drugs, by Sale USD Million (2022-2027)
  • Table 501. Mexico Orphan Drugs, by Drugs USD Million (2022-2027)
  • Table 502. Mexico Orphan Drugs, by Disease Type USD Million (2022-2027)
  • Table 503. Mexico Orphan Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 504. Orphan Drugs Sales: by Drug Type(K Units)
  • Table 505. Orphan Drugs Sales Biologics , by Region K Units (2022-2027)
  • Table 506. Orphan Drugs Sales Non-Biologics , by Region K Units (2022-2027)
  • Table 507. Orphan Drugs Sales: by Sale(K Units)
  • Table 508. Orphan Drugs Sales Generics , by Region K Units (2022-2027)
  • Table 509. Orphan Drugs Sales Prescribed , by Region K Units (2022-2027)
  • Table 510. Orphan Drugs Sales: by Drugs(K Units)
  • Table 511. Orphan Drugs Sales Revlimid , by Region K Units (2022-2027)
  • Table 512. Orphan Drugs Sales Rituxan , by Region K Units (2022-2027)
  • Table 513. Orphan Drugs Sales Opdivo , by Region K Units (2022-2027)
  • Table 514. Orphan Drugs Sales Others , by Region K Units (2022-2027)
  • Table 515. Orphan Drugs Sales: by Disease Type(K Units)
  • Table 516. Orphan Drugs Sales Oncology , by Region K Units (2022-2027)
  • Table 517. Orphan Drugs Sales Gastrointestinal , by Region K Units (2022-2027)
  • Table 518. Orphan Drugs Sales Pulmonary , by Region K Units (2022-2027)
  • Table 519. Orphan Drugs Sales Neurology , by Region K Units (2022-2027)
  • Table 520. Orphan Drugs Sales Hematology , by Region K Units (2022-2027)
  • Table 521. Orphan Drugs Sales Cardio-vascular , by Region K Units (2022-2027)
  • Table 522. Orphan Drugs Sales Metabolic disorders , by Region K Units (2022-2027)
  • Table 523. Orphan Drugs Sales Endocrinology , by Region K Units (2022-2027)
  • Table 524. Orphan Drugs Sales Infectious diseases , by Region K Units (2022-2027)
  • Table 525. Orphan Drugs Sales Others , by Region K Units (2022-2027)
  • Table 526. Orphan Drugs Sales: by Distribution Channel(K Units)
  • Table 527. Orphan Drugs Sales Hospital Pharmacies , by Region K Units (2022-2027)
  • Table 528. Orphan Drugs Sales Specialty Pharmacies , by Region K Units (2022-2027)
  • Table 529. Orphan Drugs Sales Retail pharmacies , by Region K Units (2022-2027)
  • Table 530. Orphan Drugs Sales Others , by Region K Units (2022-2027)
  • Table 531. South America Orphan Drugs Sales, by Country K Units (2022-2027)
  • Table 532. South America Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 533. South America Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 534. South America Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 535. South America Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 536. South America Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 537. Brazil Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 538. Brazil Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 539. Brazil Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 540. Brazil Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 541. Brazil Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 542. Argentina Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 543. Argentina Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 544. Argentina Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 545. Argentina Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 546. Argentina Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 547. Rest of South America Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 548. Rest of South America Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 549. Rest of South America Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 550. Rest of South America Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 551. Rest of South America Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 552. Asia Pacific Orphan Drugs Sales, by Country K Units (2022-2027)
  • Table 553. Asia Pacific Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 554. Asia Pacific Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 555. Asia Pacific Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 556. Asia Pacific Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 557. Asia Pacific Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 558. China Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 559. China Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 560. China Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 561. China Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 562. China Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 563. Japan Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 564. Japan Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 565. Japan Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 566. Japan Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 567. Japan Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 568. India Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 569. India Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 570. India Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 571. India Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 572. India Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 573. South Korea Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 574. South Korea Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 575. South Korea Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 576. South Korea Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 577. South Korea Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 578. Taiwan Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 579. Taiwan Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 580. Taiwan Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 581. Taiwan Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 582. Taiwan Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 583. Australia Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 584. Australia Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 585. Australia Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 586. Australia Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 587. Australia Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 588. Rest of Asia-Pacific Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 589. Rest of Asia-Pacific Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 590. Rest of Asia-Pacific Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 591. Rest of Asia-Pacific Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 592. Rest of Asia-Pacific Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 593. Europe Orphan Drugs Sales, by Country K Units (2022-2027)
  • Table 594. Europe Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 595. Europe Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 596. Europe Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 597. Europe Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 598. Europe Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 599. Germany Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 600. Germany Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 601. Germany Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 602. Germany Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 603. Germany Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 604. France Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 605. France Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 606. France Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 607. France Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 608. France Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 609. Italy Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 610. Italy Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 611. Italy Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 612. Italy Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 613. Italy Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 614. United Kingdom Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 615. United Kingdom Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 616. United Kingdom Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 617. United Kingdom Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 618. United Kingdom Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 619. Netherlands Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 620. Netherlands Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 621. Netherlands Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 622. Netherlands Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 623. Netherlands Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 624. Rest of Europe Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 625. Rest of Europe Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 626. Rest of Europe Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 627. Rest of Europe Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 628. Rest of Europe Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 629. MEA Orphan Drugs Sales, by Country K Units (2022-2027)
  • Table 630. MEA Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 631. MEA Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 632. MEA Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 633. MEA Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 634. MEA Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 635. Middle East Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 636. Middle East Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 637. Middle East Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 638. Middle East Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 639. Middle East Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 640. Africa Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 641. Africa Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 642. Africa Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 643. Africa Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 644. Africa Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 645. North America Orphan Drugs Sales, by Country K Units (2022-2027)
  • Table 646. North America Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 647. North America Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 648. North America Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 649. North America Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 650. North America Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 651. United States Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 652. United States Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 653. United States Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 654. United States Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 655. United States Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 656. Canada Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 657. Canada Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 658. Canada Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 659. Canada Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 660. Canada Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 661. Mexico Orphan Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 662. Mexico Orphan Drugs Sales, by Sale K Units (2022-2027)
  • Table 663. Mexico Orphan Drugs Sales, by Drugs K Units (2022-2027)
  • Table 664. Mexico Orphan Drugs Sales, by Disease Type K Units (2022-2027)
  • Table 665. Mexico Orphan Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 666. Research Programs/Design for This Report
  • Table 667. Key Data Information from Secondary Sources
  • Table 668. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Orphan Drugs: by Drug Type USD Million (2016-2021)
  • Figure 5. Global Orphan Drugs: by Sale USD Million (2016-2021)
  • Figure 6. Global Orphan Drugs: by Drugs USD Million (2016-2021)
  • Figure 7. Global Orphan Drugs: by Disease Type USD Million (2016-2021)
  • Figure 8. Global Orphan Drugs: by Distribution Channel USD Million (2016-2021)
  • Figure 9. South America Orphan Drugs Share (%), by Country
  • Figure 10. Asia Pacific Orphan Drugs Share (%), by Country
  • Figure 11. Europe Orphan Drugs Share (%), by Country
  • Figure 12. MEA Orphan Drugs Share (%), by Country
  • Figure 13. North America Orphan Drugs Share (%), by Country
  • Figure 14. Global Orphan Drugs: by Drug Type K Units (2016-2021)
  • Figure 15. Global Orphan Drugs: by Sale K Units (2016-2021)
  • Figure 16. Global Orphan Drugs: by Drugs K Units (2016-2021)
  • Figure 17. Global Orphan Drugs: by Disease Type K Units (2016-2021)
  • Figure 18. Global Orphan Drugs: by Distribution Channel K Units (2016-2021)
  • Figure 19. South America Orphan Drugs Share (%), by Country
  • Figure 20. Asia Pacific Orphan Drugs Share (%), by Country
  • Figure 21. Europe Orphan Drugs Share (%), by Country
  • Figure 22. MEA Orphan Drugs Share (%), by Country
  • Figure 23. North America Orphan Drugs Share (%), by Country
  • Figure 24. Global Orphan Drugs share by Players 2021 (%)
  • Figure 25. Global Orphan Drugs share by Players (Top 3) 2021(%)
  • Figure 26. Global Orphan Drugs share by Players (Top 5) 2021(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 30. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol Myers Squibb (United States) Revenue: by Geography 2021
  • Figure 32. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celgene (United States) Revenue: by Geography 2021
  • Figure 34. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 38. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A. (France) Revenue: by Geography 2021
  • Figure 40. Alexion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Alexion Pharmaceuticals Inc. (United States) Revenue: by Geography 2021
  • Figure 42. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 43. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 44. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 45. Novo Nordisk (Denmark) Revenue: by Geography 2021
  • Figure 46. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 47. AstraZeneca plc (United Kingdom) Revenue: by Geography 2021
  • Figure 48. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 49. Eisai Co., Ltd. (Japan) Revenue: by Geography 2021
  • Figure 50. Daiichi Sankyo Company (Japan) Revenue, Net Income and Gross profit
  • Figure 51. Daiichi Sankyo Company (Japan) Revenue: by Geography 2021
  • Figure 52. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 53. Bayer (Germany) Revenue: by Geography 2021
  • Figure 54. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 55. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 56. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 57. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 58. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 59. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 60. Biogen Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 61. Biogen Inc. (Switzerland) Revenue: by Geography 2021
  • Figure 62. Global Orphan Drugs: by Drug Type USD Million (2022-2027)
  • Figure 63. Global Orphan Drugs: by Sale USD Million (2022-2027)
  • Figure 64. Global Orphan Drugs: by Drugs USD Million (2022-2027)
  • Figure 65. Global Orphan Drugs: by Disease Type USD Million (2022-2027)
  • Figure 66. Global Orphan Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 67. South America Orphan Drugs Share (%), by Country
  • Figure 68. Asia Pacific Orphan Drugs Share (%), by Country
  • Figure 69. Europe Orphan Drugs Share (%), by Country
  • Figure 70. MEA Orphan Drugs Share (%), by Country
  • Figure 71. North America Orphan Drugs Share (%), by Country
  • Figure 72. Global Orphan Drugs: by Drug Type K Units (2022-2027)
  • Figure 73. Global Orphan Drugs: by Sale K Units (2022-2027)
  • Figure 74. Global Orphan Drugs: by Drugs K Units (2022-2027)
  • Figure 75. Global Orphan Drugs: by Disease Type K Units (2022-2027)
  • Figure 76. Global Orphan Drugs: by Distribution Channel K Units (2022-2027)
  • Figure 77. South America Orphan Drugs Share (%), by Country
  • Figure 78. Asia Pacific Orphan Drugs Share (%), by Country
  • Figure 79. Europe Orphan Drugs Share (%), by Country
  • Figure 80. MEA Orphan Drugs Share (%), by Country
  • Figure 81. North America Orphan Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Bristol Myers Squibb (United States)
  • Celgene (United States)
  • Roche Holding AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • Alexion Pharmaceuticals Inc. (United States)
  • Eli Lilly and Company (United States)
  • Novo Nordisk (Denmark)
  • AstraZeneca plc (United Kingdom)
  • Eisai Co., Ltd. (Japan)
  • Daiichi Sankyo Company (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Johnson & Johnson (United States)
  • Biogen Inc. (Switzerland)
Additional players considered in the study are as follows:
Shire Plc (United States) , Amgen Inc. (United States)
Select User Access Type

Key Highlights of Report


Feb 2023 213 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Orphan Drugs Quantitative research analysis
Global Orphan Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Rare Diseases " is seen as one of major growth factors of Orphan Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Orphan Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Orphan Drugs Report?

Have a Query? Click Here

Other Related Reports

Diptheria Vaccine Comprehensive Study by Type (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quaracel), Disease Type (Diphtheria, Tetanus, Pertussis), Packaging Type (0.5 ML, 1 ML, 2 ML, Others), A...
$ 3450
Bio-pharma Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, G...
$ 3750
Polio Vaccines Comprehensive Study by Type (IPV (Inactivated Poliovirus Vaccine), OPV (Oral Polio Vaccine)), Application (Hospital, Clinics, Public Services, Others) Players and Region - Global Marke...
$ 3500
Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail ...
$ 3500
Clomifene Citrate Comprehensive Study by Application (Hospital, Clinics, Fertility Center), Form (Tablet, Injection), Distribution Channel (Hospital Pharmacies, Medical Stores, Online Pharmacies), En...
$ 3800
Frankincense Oil Comprehensive Study by Type (Natural Frankincense Oil, Synthetic Frankincense Oil), Application (Medicine, Skin care, Oral Care , Others), Distribution Channel (Direct, Indirect (Spe...
$ 3500